keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer ad

keyword
https://www.readbyqxmd.com/read/28228218/-thioridazine-sensitizes-apoptotic-effect-of-trail-in-human-lung-cancer-pc9-cells-through-er-stress-mediated-up-regulation-of-dr5
#1
Juan Li, Yi Wang, Liu Liu, Yuan Yuan, Yangyi Bao
BACKGROUND: Tumor necrosis factor-related apoptosis-inducting ligand (TRAIL) can induce apoptosis of tumor cells, however, various of tumor cells may survive because of resistance to TRAIL-mediated apoptosis. This study is to observe the proliferation inhibition effect of TRAIL sensitized by thioridazine on PC9 cells through endoplasmic reticulum (ER) stress mediated up-regulation of death receptor 5 (DR5) and investigate its mechanism. METHODS: PC9 cells were treated with different concentrations of thioridazine and TRAIL alone or in combination...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28225501/the-effect-of-induction-chemotherapy-in-patients-with-locally-advanced-nonsmall-cell-lung-cancer-who-received-chemoradiotherapy-a-systematic-review-and-meta-analysis
#2
Hui Luo, Xinshuang Yu, Ning Liang, Jian Xie, Guodong Deng, Qiqi Liu, Jingxin Zhang, Jiandong Zhang, Hong Ge
BACKGROUND: The efficacy and toxicity of induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) in patients with locally advanced nonsmall cell lung cancer (NSCLC) is unclear, we performed a systematic review and meta-analysis of published papers to quantitatively evaluate the potential benefit of induction chemotherapy. METHODS: Eligible studies of induction chemotherapy and chemoradiotherapy were retrieved through extensive searches of the PubMed, Science Direct, Embase, and Cochrane library databases from 1994 to 2015...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28188101/antiangiogenic-therapy-in-advanced-non-small-cell-lung-cancer-a-meta-analysis-of-phase-iii-randomized-trials
#3
REVIEW
Jacques Raphael, Kelvin Chan, Safiya Karim, Robert Kerbel, Henry Lam, Keemo Delos Santos, Ronak Saluja, Sunil Verma
We conducted a meta-analysis to evaluate the efficacy of adding any antiangiogenic therapy (AT) to the standard of care in advanced non-small-cell lung cancer (NSCLC). The electronic databases Ovid PubMed, Cochrane Central Register of Controlled Trials, and Embase were searched to identify eligible trials. We included all phase III randomized trials with any line and type of treatment, histology. and AT dose. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and pooled odds ratio (OR) for overall response rates (RR) were calculated...
January 12, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28158453/systematic-lymphadenectomy-versus-sampling-of-ipsilateral-mediastinal-lymph-nodes-during-lobectomy-for-non-small-cell-lung-cancer-a-systematic-review-of-randomized-trials-and-a-meta-analysis
#4
Sahar Mokhles, Fergus Macbeth, Tom Treasure, Riad N Younes, Robert C Rintoul, Francesca Fiorentino, Ad J J C Bogers, Johanna J M Takkenberg
No abstract text is available yet for this article.
January 30, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28156583/developing-a-supportive-oncology-program-in-a-cancer-institute-needs-assessment
#5
Tara Liberman, James D'Olimpio, Maria Carney
: 141 Background: Cancer patients experience significant symptom and psychosocial burden (Temel JS, et. al. N Engl J Med. 2010 Aug 19; 363(8):733-42. Early palliative care for patients with metastatic non-small-cell lung cancer.). Integration of supportive oncology programs within cancer centers has developed since the findings of Temel and Jackson. Addressing a growing need to manage patients comprehensively, the Northwell Health Divisions of Geriatric and Palliative Medicine and Hematology and Oncology partnered to initiate a community-based supportive oncology program...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156575/using-a-values-assessment-as-a-bridge-to-advance-care-planning-results-of-1286-patient-reports
#6
Cynthia Taniguchi, Kathryn J Eagye, Susan Ash-Lee, Angela Kalisiak, Sabrina Q Mikan, Nicole Hartung
: 12 Background: Recent studies have shown that formal Palliative Care (PC) improves care at the end of life for cancer patients. The role of communication in PC is not defined. Other studies have shown that communication alone can be associated with better end of life outcomes. The US Oncology Network developed and tested a Values Assessment (VA) instrument for routinely broaching difficult topics to facilitate more formal advance care planning (ACP). The results of the first 28 months of the program on over 1200 patients are reported here...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152835/physician-decisions-related-to-maintenance-therapy-for-advanced-non-small-cell-lung-cancer-nsclc-in-the-united-states-us
#7
Sarah Goring, Kerstin Mueller, Lisa M Hess, Ana Belen Oton, Catherine Muehlenbein, Yajun Zhu, Himani Aggarwal, Mohamed K Mohamed, Benjamin Philip Levy, Katherine B Winfree
: 182 Background: In 2006, maintenance therapy was added as a treatment guideline for patients with advanced non-squamous (nsq) NSCLC. This study aimed to identify patient- and disease-related factors that impact maintenance therapy decision making. METHODS: An online discrete choice survey was administered to physicians currently managing patients with advanced nsq NSCLC in the US. Physicians viewed 12 patient profiles differing in levels of the following attributes: 1st line treatment response (complete, partial, stable, progression), adverse events during 1st line therapy (none, mild, moderate, severe), comorbidities (none, mild renal, severe renal, other), patient motivation/convenience (+/+, +/-, -/+, -/-), patient insurance co-pay rate (0, 5, 10, 20%), and age (45, 58, 68, 80 years)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152789/does-oncology-patient-reported-healthcare-experience-vary-by-site-of-care-soc
#8
Adrianne Waldman Casebeer, Sari Hopson, Joseph Dye, Zhuliang Tao, Andrew M Howe, Stephen Stemkowski, Jeffrey Patton, Art Small, Anthony Masaquel
: 71 Background: Patients with cancer are increasingly receiving chemotherapy infusions in a hospital outpatient (HO) as compared to the physician practice setting (PO). Previous research has focused on SOC differences in economic measures, such as healthcare costs, in commercially insured populations. This study investigates SOC differences in patients' reported healthcare experience for a mostly Medicare population. METHODS: A convenience sample of 2,604 Humana members with cancer of the breast, lung, colon/rectum or NHL/CLL and treated in 2014 received a survey by mail to capture patient reported healthcare experiences...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28150878/pathway-analysis-of-published-genome-wide-association-studies-of-lung-cancer-a-potential-role-for-the-cyp4f3-locus
#9
Jieyun Yin, Hongliang Liu, Zhensheng Liu, Kouros Owzar, Younghun Han, Li Su, Yongyue Wei, Rayjean J Hung, Yonathan Brhane, John McLaughlin, Paul Brennan, Heike Bickeboeller, Albert Rosenberger, Richard S Houlston, Neil Caporaso, Maria Teresa Landi, Joachim Heinrich, Angela Risch, David C Christiani, Christopher I Amos, Qingyi Wei
The Fatty acids (FAs) metabolism is suggested to play a pivotal role in the development of lung cancer, we explored that by conducting pathway-based analysis. We performed a meta-analysis of published datasets of six genome wide association studies (GWASs) from the Transdisciplinary Research in Cancer of the Lung (TRICL) consortium, which included 12,160 cases with lung cancer and 16,838 cancer-free controls. A total of 30,722 single-nucleotide polymorphisms (SNPs) from 317 genes relevant to FA metabolic pathways were identified...
February 2, 2017: Molecular Carcinogenesis
https://www.readbyqxmd.com/read/28145884/the-significance-of-programmed-cell-death-ligand-1-expression-in-resected-lung-adenocarcinoma
#10
Shafei Wu, Xiaohua Shi, Jian Sun, Yuanyuan Liu, Yufeng Luo, Zhiyong Liang, Jinghui Wang, Xuan Zeng
BACKGROUND: Lung adenocarcinoma (AD) is a common variant of non-small cell lung cancer (NSCLC). Programmed cell death protein 1/programmed cell death ligand 1 (PD1/PD-L1) are promising immunotherapy targets and its expression may be an important biomarker of predicting clinical response. In this study, we evaluated PD-L1 expression in conjunction with clinicopathological characteristics and outcomes in resected lung adenocarcinoma. RESULTS: This study included 133 cases of lung adenocarcinoma...
January 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28135143/italian-multicenter-phase-iii-randomized-study-of-cisplatin-plus-etoposide-with-or-without-bevacizumab-as-first-line-treatment-in-extensive-disease-small-cell-lung-cancer-the-goirc-aifa-farm6pmfjm-trial
#11
Marcello Tiseo, Luca Boni, Francesca Ambrosio, Andrea Camerini, Editta Baldini, Saverio Cinieri, Matteo Brighenti, Francesca Zanelli, Efisio Defraia, Rita Chiari, Claudio Dazzi, Carmelo Tibaldi, Gianni Michele Turolla, Vito D'Alessandro, Nicoletta Zilembo, Anna Rita Trolese, Francesco Grossi, Ferdinando Riccardi, Andrea Ardizzoni
Purpose Considering promising results in phase II studies, a randomized phase III trial was designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide for treatment of extensive-disease (ED) small-cell lung cancer (SCLC). Patients and Methods Treatment-naive patients with ED-SCLC were randomly assigned to receive either cisplatin plus etoposide (arm A) or the same regimen with bevacizumab (arm B) for a maximum of six courses. In the absence of progression, patients in arm B continued bevacizumab alone until disease progression or for a maximum of 18 courses...
January 30, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28135117/an-11-year-study-of-home-hospice-service-trends-in-singapore-from-2000-to-2010
#12
Benedict John Ho, Ramaswamy Akhileswaran, Grace Su Yin Pang, Gerald Choon Huat Koh
BACKGROUND: Hospice care is most appropriate when a patient no longer benefits from curative treatment and has limited life expectancy. These patients may suffer from any type of life-limiting illness, including end-stage cancer, end-stage heart disease, end-stage renal failure, AIDS, and Alzheimer's disease, among other illnesses. Patients are managed on their pain and symptoms and home hospice care manages these patients in the comfort of their own home, enabling patients to spend their last days with dignity and have a good quality of life...
January 30, 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28129654/time-dependent-modulation-of-tumor-radiosensitivity-by-a-pan-hdac-inhibitor-abexinostat
#13
Sofia Rivera, Céline Leteur, Frédérique Mégnin, Frédéric Law, Isabelle Martins, Ioana Kloos, Stéphane Depil, Nazanine Modjtahedi, Jean Luc Perfettini, Christophe Hennequin, Eric Deutsch
Despite prominent role of radiotherapy in lung cancer management, there is an urgent need for strategies increasing therapeutic efficacy. Reversible epigenetic changes are promising targets for combination strategies using HDAC inhibitors (HDACi).Here we evaluated on two NSCLC cell lines, the antitumor effect of abexinostat, a novel pan HDACi combined with irradiation in vitro in normoxia and hypoxia, by clonogenic assays, demonstrating that abexinostat enhances radiosensitivity in a time dependent way with mean SER10 between 1...
January 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28126888/detection-of-micrometastases-using-spect-fluorescence-dual-modality-imaging-in-a-cea-expressing-tumor-model
#14
Marlène C H Hekman, Mark Rijpkema, Desirée Bos, Egbert Oosterwijk, David M Goldenberg, Peter F A Mulders, Otto C Boerman
BACKGROUND: Intraoperative dual-modality imaging can help the surgeon distinguish tumor from normal tissue. This technique may prove particularly valuable if small tumors need to be removed that are difficult to detect with the naked eye. The humanized anti-carcinoembryonic antigen (anti-CEA) monoclonal antibody, labetuzumab (hMN-14), can be used as a tumor targeting agent in colorectal cancer (CRC), since CEA is overexpressed in approximately 95% of CRC. Dual-labeled labetuzumab, labeled with both a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (Indium-111), can be used as a tracer for dual-modality imaging...
January 26, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28119362/lkb1-expression-correlates-with-increased-survival-in-advanced-non-small-cell-lung-cancer-patients-treated-with-chemotherapy-and-bevacizumab
#15
Laura Bonanno, Angela De Paoli, Elisabetta Zulato, Giovanni Esposito, Fiorella Calabrese, Adolfo Favaretto, Antonio Santo, Alessandro Del Conte, Marco Chilosi, Francesco Oniga, Gabriella Sozzi, Massimo Moro, Francesco Ciccarese, Giorgia Nardo, Roberta Bertorelle, Cinzia Candiotto, Gian Luca De Salvo, Alberto Amadori, PierFranco Conte, Stefano Indraccolo
PURPOSE: LKB1 is a key sensor of metabolic stress, including hypoxia and glucose deprivation, two features of the tumor microenvironment exacerbated by antiangiogenic therapy. We investigated the role of LKB1 as potential predictive marker of sensitivity to bevacizumab in advanced non-small cell lung cancer (aNSCLC). EXPERIMENTAL DESIGN: We retrospectively analyzed LKB1 expression by immunohistochemistry in 98 samples out of 125 aNSCLC patients, including 59 patients treated with chemotherapy (CT) and 39 treated with CT plus bevacizumab...
January 24, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28117012/current-status-and-perspectives-regarding-the-therapeutic-potential-of-targeting-egfr-pathway-by-curcumin-in-lung-cancer
#16
Mojtaba Shafiee, Elham Mohamadzade, Soudabeh ShahidSales, Samaneh Khakpouri, Mina Maftouh, Seyed Alireza Parizadeh, Seyed Mahdi Hasanian, Amir Avan
Lung cancer is among the leading cause of cancer-related-deaths and non-small cell lung cancer (NSCLC) is the most common form of lung cancer. More than 70% of NSCLC patients have locally advanced or metastatic disease at diagnosis, which are then being treated with platinum-based chemotherapy or epidermal-growth-factor-receptor (EGFR) inhibitors in patients harboring activating EGFR-mutations. Several molecules which target multiple ErbB receptors and EGFR, have been developed, including gefitinib and erlotinib, although most of the patients become resistance...
January 23, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28105156/establishment-of-a-first-line-second-line-treatment-model-for-human-pulmonary-adenocarcinoma
#17
Lining Wang, Yu Wang, Qi Guan, Yong Liu, Tianyi He, Jiaru Wang
Lung cancer is one of the most prevalent types of cancer in the world. Surgery, chemotherapy and radiotherapy are used clinically as treatments for numerous cancers. Due to the appearance of drug resistance, the remission rate is limited to 40-50%. Docetaxel and pemetrexed are two drugs commonly used, and their effects in single-phase cell culture are well known. From the pharmacological point of view, it appears rational to hypothesize that sequential therapy effects can show better outcomes compared with traditional single-phase experiments...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28088881/an-industry-update-the-latest-developments-in-therapeutic-delivery
#18
Iain Simpson
This Industry Update covers the period from 1 October through to 31 October 2016, and is based on information sourced from company press releases, scientific literature, patents and various news websites. The month saw several news items covering drug-delivery devices, including a new sensor to monitor and support the use of inhalers; launch in the UK of a new autoinjector for Cimzia(®), UCB's rheumatoid arthritis drug; and approval of Roche's Lucentis(®) in a prefilled syringe. Research was also published to show the value of continuous blood pressure monitoring in dementia management...
February 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28068937/the-efficacy-and-roles-of-combining-temozolomide-with-whole-brain-radiotherapy-in-protection-neurocognitive-function-and-improvement-quality-of-life-of-non-small-cell-lung-cancer-patients-with-brain-metastases
#19
Xia Deng, Zhen Zheng, Baochai Lin, Huafang Su, Hanbin Chen, Shaoran Fei, Zhenghua Fei, Lihao Zhao, Xiance Jin, Cong-Ying Xie
BACKGROUND: Brain metastasis (BM) is a poor prognostic factor for non-small-cell lung cancer (NSCLC). The efficacy and roles of combining temozolomide (TMZ) with whole brain radiotherapy (WBRT) in protection neurocognitive function (NCF) and improvement quality of life (QOL) were investigated and compared with WBRT alone in the treatment of NSCLC patients with BM. METHODS: A total of 238 NSCLC patients with BM were reviewed and categorized into WBRT plus TMZ (RCT) arm and WBRT alone (RT), respectively...
January 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28063862/anxiety-after-diagnosis-predicts-lung-cancer-specific-and-overall-survival-in-patients-with-stage-iii-non-small-cell-lung-cancer-a-population-based-cohort-study
#20
Andrea Vodermaier, Sarah Lucas, Wolfgang Linden, Robert Olson
CONTEXT: The question as to whether anxiety and depression are related to mortality in patients with lung cancer is inconclusive. OBJECTIVE: Therefore, the present study is examining associations of anxiety and depression in a large representative sample of patients with stage III non-small cell lung cancer. METHODS: Patients (n=684) were routinely assessed for anxiety and depression with the PsychoSocial Screen for Cancer (PSSCAN) questionnaire after diagnosis of lung cancer and before treatment initiation between 2004 and 2010...
January 4, 2017: Journal of Pain and Symptom Management
keyword
keyword
117397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"